Integrin
All Product Categories
-
Integrin Inhibitors
(180)
View all products
-
Integrin Agonists
(5)
View all products
-
Integrin Antagonists
(68)
View all products
-
Integrin Activators
(7)
View all products
-
Integrin Modulators
(5)
View all products
-
Integrin Chemicals
(2)
View all products
-
Integrin Inducers
(2)
View all products
-
Integrin Degrader
(1)
View all products
-
Integrin Controls
(3)
View all products
-
Integrin Substrate
(1)
View all products
-
Integrin Ligands
(15)
View all products
-
Integrin 関連製品 (379)
関連製品 (379)
-
Endothelin-3, human, mouse, rabbit, rat TFA
0 Images製品番号: HY-P0204A純度: 99.57%別名: Endothelin 3 (Rat,Human) TFAEndothelin-3, human, mouse, rabbit, rat TFA (Endothelin 3 (Rat,Human) TFA) is an adhesion stimulant. Endothelin-3, human, mouse, rabbit, rat TFA stimulates the adhesion of enteric neural crest cells to various ECM components. Endothelin-3, human, mouse, rabbit, rat TFA plays an important role in the maintenance and self-renewal of intestinal progenitor cells, participates in the migration of enteric neural crest cells, and helps maintain a suitable environment for the colonization of enteric neural crest cells. Endothelin-3, human, mouse, rabbit, rat TFA acts synergistically with the β1-integrin signaling pathway during enteric nervous system development. Endothelin-3, human, mouse, rabbit, rat TFA can be used in studies related to distal aganglionosis.
-
Sigvotatug
0 Images別名: SGN-B6A antibodySigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957).
-
A-205804
0 ImagesA-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
-
Natalizumab (Anti-CD49d)
0 Images別名: AN100226; BG00002Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses.
-
Abciximab
0 Images別名: C7E3Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
-
Leukadherin-1
0 ImagesLeukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling.
-
ABH hydrochloride
0 ImagesABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis.
-
OSU-T315
0 ImagesOSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.
-
Sigvotatug vedotin
0 Images別名: SGN-B6A; PF-08046047SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162).
-
OS-2966
0 Images製品番号: HY-P990643純度: 99.62%OS-2966 is a humanized neutralizing monoclonal antibody (huIgG1κ) targeting human CD29 (β1 integrin/ITGB1). OS-2966 blocks integrin β1 signaling, inhibits tumor cell proliferation, invasion, migration and mesenchymal phenotype, and enhances the efficacy of oncolytic herpes simplex virus-1 (oHSV) and anti-angiogenic therapies. OS-2966 can be used in research related to triple-negative breast cancer, high-grade meningioma, glioblastoma and ovarian cancer.
-
αvβ1 integrin-IN-1 TFA
0 Images製品番号: HY-100445A純度: 98.28%
-
Etaracizumab
0 Images別名: LM609; MEDI-522Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Gly-Arg-Gly-Asp-Ser
0 Images別名: GRGDSGly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ～5 and ～6.5 μM
-
Carotegrast methyl
0 Images別名: AJM300
-
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32)
0 Images製品番号: HY-P990203純度: 99.08%Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis.
-
GRGDSPK
0 Images別名: EMD 56574GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption.
-
Tirofiban hydrochloride monohydrate
0 Images別名: L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrateTirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
